Infectious Disease

Should ACAM2000 be a first-line monkeypox vaccine? Two experts debate

October 21, 2022

4 minutes watch

Source/Disclosures

Published by:

infectious disease news logo

sources:

Healio Interview.

Disclosures:
Havlir and Holland report no relevant financial disclosures.

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on . ” data-action=subscribe> Subscribe

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

Back to Healio

WASHINGTON — Should ACAM2000 be a first-line vaccine in the current monkeypox outbreak? That was the topic of a pro/con debate during a “clinical controversies” session at IDWeek.

In this video filmed before their debate, diane HavlirMD, professor of medicine at the University of California, San Francisco, and chief of the division of HIV and infectious diseases at San Francisco General Hospital, argues that ACAM2000 should not be a first-line vaccine because it is more toxic and more complicated to administer than the Jynneos vaccine, which is the main vaccine being used during the monkeypox outbreak.

David P. Holland, MD, MHS, FIDSA, an associate professor of medicine in the division of infectious diseases at Emory University and chief clinical officer at the Fulton County Board of Health in Atlanta, argues that patients should be allowed to choose between the two vaccines.

References:

CDC. Interim clinical considerations for use of Jynneos and ACAM2000 vaccines during the 2022 US monkeypox outbreak. https://www.cdc.gov/poxvirus/monkeypox/health-departments/vaccine-considerations.html. Updated Oct. 19, 2022. Accessed Oct. 21, 2022.

Havlir D, Holland DP. ACAM2000 should be a first-line vaccine in the current monkeypox outbreak: Pro/Con. Presented at: IDWeek; october 19-23, 2022; Washington (hybrid meeting).

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on . ” data-action=subscribe> Subscribe

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

Back to Healio

thin banner showing an illustration of infectious disease

IDWeek

Related Articles